CLINICAL_TRIALS
ClinicalTrials.gov record update
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05440422
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:03.280756+00:00
- Published At
- 2026-04-06T00:00:00+00:00
- Record Updated At
- 2026-04-06
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Systemic Lupus Erythematosus", "Cardiovascular Disease", "Premature Atherosclerosis"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-06"- protocolSection.identificationModule.nctId
"NCT05440422"- protocolSection.identificationModule.officialTitle
"The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.